Related Experiment Video
Updated: May 1, 2026

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica
Published on: October 28, 2022
Insights into Silica-Induced Lung Fibrosis: Fibrotic Gene Signatures, Pathways, and Therapeutic Opportunities
Fahad Alsohime1,2, Narjes Saheb Sharif-Askari3,4, Nasser Saleh Alharbi1
1Pediatric Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Introduction:
Silica exposure is a significant environmental hazard linked to lung inflammation and fibrosis. Despite general protective measures, there remains a critical need for pharmacological interventions targeting the molecular mechanisms of silica-induced lung injury and fibrosis.
Methods:
In silico reanalysis of publicly available transcriptomic datasets (GSE250537, GSE142446) from silica-exposed Fischer-344 rats was conducted to investigate molecular pathways and therapeutic targets. Rats were exposed to crystalline silica via inhalation, and lung/blood transcriptomes were analyzed at 1 day, 3, 6, and 9 months post-exposure. Differential expression, gene set enrichment analysis (GSEA), protein-protein interaction (PPI) clustering, and drug-gene matching (Open TG-GATEs) were performed, followed by in vivo validation of simvastatin in a murine silica fibrosis model.
Results:
GSEA revealed activation of fibro-inflammatory and aging pathways in lung tissue, including TGF-beta, NOD-like receptor protein 3, and TNF-α signaling, with limited effects in blood. Differential expression identified 12 fibrotic markers consistently upregulated in lung tissue, such as Cxcl6, Mmp12, and S100a9, implicated in inflammation, tissue remodeling, and fibrosis. Temporal analysis showed prolonged upregulation up to 9 months post-exposure. Protein-protein interaction networks highlighted clusters related to chemokine signaling, tissue remodeling, and matrix metalloproteinases. Using the Open TG-GATEs database, 179 pharmacological agents were identified, with 37 targeting five or more fibrotic genes. Notable candidates included non-steroidal anti-inflammatory drugs, captopril, and simvastatin. In vivo validation in a silica-induced murine fibrosis model showed that simvastatin significantly reduced key fibro-inflammatory genes and attenuated increases in fibrotic markers in lung tissue.
Conclusion:
These findings provide insights into silica immunopathology and potential drug repurposing strategies; however, further studies are warranted to elucidate mechanisms and evaluate therapeutic efficacy in clinical settings.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation

